Unassociated Document
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): March 26, 2008
BIOPHAN
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-26057
|
82-0507874
|
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
15 Schoen
Place, Pittsford, New York 14534
(Address
of principal executive offices) (Zip Code)
Copies
to:
Gregory
Sichenzia, Esq.
Andy
Smith, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway
New York,
New York 10006
Phone:
(212) 930-9700
Fax:
(212) 930-9725
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Effective
as of March 31, 2009, Guenter Jaensch resigned as a member of the
Board of Directors of Biophan Technologies, Inc., a Nevada corporation (the
“Company”). No
reason for the resignation was mentioned in the letter of resignation, a copy of
which is filed herewith. However, the Company believes it was not due
to any disagreement with the Company.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
A copy of
the notice of resignation submitted by Mr. Jaensch to the Company, dated as of
March 22, 2009, is listed in the Index to Exhibits which immediately follows the
signature page hereto. A copy of this current report was furnished to
Mr. Jaensch prior to its filing.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
BIOPHAN
TECHNOLOGIES, INC. |
|
| |
|
|
|
|
Dated:
March 31, 2009
|
By:
|
/s/ John
Lanzafame |
|
| |
|
Name:
John Lanzafame |
|
| |
|
Title:
Chief Executive Officer |
|
| |
|
|
|